Two-year virologic outcomes of an alternative AIDS care model: Evaluation of a peer health worker and nurse-staffed community-based program in uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 3, 2009, Pages 276-282

  Chang, Larry W ^a   Alamo, Stella ^b   Guma, Samuel ^b   Christopher, Jason ^b   Suntoke, Tara ^c   Omasete, Richard ^b   Montis, Jennifer P ^b   Quinn, Thomas C ^a,c   Juncker, Margrethe ^b   Reynolds, Steven J ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Reach Out Mbuya Parish HIV/AIDS Initiative   (Uganda)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adherence; Africa; Antiretroviral treatment; Community health services; Nurses; Program evaluation

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; STAVUDINE; TUBERCULOSTATIC AGENT; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COMMUNITY HEALTH NURSING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; UGANDA; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; WORLD HEALTH ORGANIZATION; COMMUNITY CARE; HEALTH CARE QUALITY; MANPOWER; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PEER GROUP; STANDARD; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMMUNITY HEALTH SERVICES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, ORGANIZATIONAL; NURSES; PATIENT COMPLIANCE; PEER GROUP; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; UGANDA; VIRAL LOAD;

EID: 63149102742     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181988375     Document Type: Article

References (48)

1. Van Damme W, Kober K, Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS. 2006;20:653-656.
2. Colebunders R, Ronald A, Katabira E, et al. Rolling out antiretrovirals in Africa: there are still challenges ahead. Clin Infect Dis. 2005;41:386-389.
3. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13:367-373.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
5. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-F43.
6. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
7. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334.
8. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006;42:252-259.
9. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315-320.
10. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
11. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. lancet. 2006; 368:1587-1594.
12. Akileswaran C, Lurie MN, Flanigan TP, et al. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41: 376-385.
13. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224.
14. Reynolds SJ, Bartlett JG, Quinn TC, et al. Antiretroviral therapy where resources are limited. N Engl J Med. 2003;348:1806-1809.
15. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19: 1243-1249.
16. Bangsberg DR, Ware N, Simoni JM. Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS. 2006;20:140-141; Author reply 141-142.
17. Moore DM, Mermin J, Awor A, et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr. 2006;43:436-439.
18. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
19. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
20. World Health Organization. Scaling Up HIV/AIDS Care: Service Delivery and Human Resource Perspectives. Geneva: World Health Organization; 2004.
21. World Health Organization. The World Health Report 2006: Working Together for Health. WHO: Geneva, 2006.
22. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281-288.
23. Walton DA, Farmer PE, Lambert W, et al. Integrated HIV prevention and care strengthens primary health care: lessons from rural Haiti. J Public Health Policy. 2004;25:137-158.
24. Green EC, Halperin DT, Nantulya V, et al. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav. 2006;10:335-346; Discussion 347-350.
25. Van Damme W, Kober K, Laga M. The real challenges for scaling up ART in sub-Saharan Africa. AIDS. 2006;20:653-656.
26. Colebunders R, Ronald A, Katabira E, et al. Rolling out antiretrovirals in Africa: there are still challenges ahead. Clin Infect Dis. 2005;41:386-389.
27. Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13:367-373.
28. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131:81-87.
29. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS. 1999;13:F35-F43.
30. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
31. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334.
32. Spacek LA, Shihab HM, Kamya MR, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006;42:252-259.
33. Bekker LG, Myer L, Orrell C, et al. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006;96:315-320.
34. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
35. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. lancet. 2006; 368:1587-1594.
36. Akileswaran C, Lurie MN, Flanigan TP, et al. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41: 376-385.
37. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224.
38. Reynolds SJ, Bartlett JG, Quinn TC, et al. Antiretroviral therapy where resources are limited. N Engl J Med. 2003;348:1806-1809.
39. Gill CJ, Hamer DH, Simon JL, et al. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19: 1243-1249.
40. Bangsberg DR, Ware N, Simoni JM. Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS. 2006;20:140-141; Author reply 141-142.
41. Moore DM, Mermin J, Awor A, et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr. 2006;43:436-439.
42. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360:34-40.
43. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
44. World Health Organization. Scaling Up HIV/AIDS Care: Service Delivery and Human Resource Perspectives. Geneva: World Health Organization; 2004.
45. World Health Organization. The World Health Report 2006: Working Together for Health. WHO: Geneva, 2006.
46. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281-288.
47. Walton DA, Farmer PE, Lambert W, et al. Integrated HIV prevention and care strengthens primary health care: lessons from rural Haiti. J Public Health Policy. 2004;25:137-158.
48. Green EC, Halperin DT, Nantulya V, et al. Uganda's HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav. 2006;10:335-346; Discussion 347-350.